Pharmacogenomics uses information about your DNA to help your doctor choose the most effective medicine and dose for you. CERSI-PGx is dedicated to making this “personalized medicine” a safe and standard part of care across the NHS by involving patient voices at every stage of our research.
- Understanding Pharmacogenomics
- Our Commitment to Patients (Work Package 5)
- How You Can Get Involved
Understanding Pharmacogenomics
Most medicines are “one size fits all,” but DNA—your body’s unique instruction manual—can affect how you react to certain drugs. A simple test can help predict if a medicine will work for you or if it might cause an unwanted reaction.
Our Commitment to Patients (Work Package 5)
Work Package 5 (WP5) focuses on Patient and Public Involvement and Engagement (PPIE). We ensure that regulatory pathways and testing practices are developed with the priorities of patients in mind.
Plain English Descriptions of our Guidelines
Our PPIE Group, whose members belong to VOCAL, Bringing People & Health Research Together | We Are Vocal has supported the development of our guidelines, and produced a Plain English summary of each:
https://cersi-pgx.org/wp-content/uploads/2026/05/Plain-English-Summary-Clopidogrel-and-CYP2C19.pdf
https://cersi-pgx.org/wp-content/uploads/2026/07/Plain-English-Summary-irinotecan-and-UGT1A1.pdf
How You Can Get Involved
We offer regular opportunities for patients and the public to contribute to our work through workshops, surveys, and consultations. Your experiences help us create clearer patient information and better testing guidelines for the future.

Learn more about each work package →
- WP1 – Developing UK-Based Guidelines
- WP2 – Pathway for Industry Pharmacogenomic Testing
- WP3 – Education and Training
- WP4 – Health Economics of PGx
- WP5 – Patient and Public Engagement
News & Events
-
CERSI-PGx Workshop – 10 September 2026
We would like to extend an invitation to all our CERSI-PGx friends and colleagues to join us at the next CERSI-PGx on-line workshop to be…
-
CERSI-PGx 5th Guideline is published!
We are pleased to share the news that our guideline on MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity has been published in the BCJP. Huge…
-
Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study | The Pharmacogenomics Journal
We are delighted that our WP5 leads John McDermott and Ramona Moldovan along with colleagues have published an article in the Pharmacogenomics Journal. DTC PGx…
-
The UK Industry PGx Regulatory Portal Product Discovery Report
Presents a comprehensive analysis and vision for a digital regulatory portal designed to streamline the compliance journey for pharmacogenomic (PGx) testing companies within the UK…
-
CERSI-PGx Guideline UGT1A1 genotype testing for irinotecan published!
Today sees the publication of the 4th UK CERSI-PGx guideline on the use of UGT1A1 genotype testing to support the safe prescribing of irinotecan. Irinotecan…
-
CERSI-PGx Commercial Laboratory Workshop
Date Confirmed: Invitation to CERSI-PGx Commercial Laboratory Workshop Tues 30th June 1.00 – 2.30pm Invitation to CERSI-PGx Commercial Laboratory WorkshopAre you a commercial laboratory based in…


